Population pharmacokinetic model of PI-88, a heparanase inhibitor

被引:0
作者
Susan F. Hudachek
S. Gail Eckhardt
Barbara Hicks
Daniel L. Gustafson
机构
[1] Colorado State University,Animal Cancer Center, Department of Clinical Sciences
[2] University of Colorado Cancer Center,Developmental Therapeutics Program
[3] Progen Pharmaceuticals Ltd,undefined
来源
Cancer Chemotherapy and Pharmacology | 2010年 / 65卷
关键词
Population pharmacokinetics; NONMEM; PI-88; Heparanase;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:743 / 753
页数:10
相关论文
共 142 条
[1]  
Baker SD(2002)Role of body surface area in dosing of investigational anticancer agents in adults, 1991–2001 J Natl Cancer Inst 94 1883-1888
[2]  
Verweij J(2006)A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors Clin Cancer Res 12 5471-5480
[3]  
Rowinsky EK(1991)The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh Clin Endocrinol (Oxf) 35 409-412
[4]  
Donehower RC(1969)Absorption of injected insulin: a clinical-pharmacological study Acta Pharmacol Toxicol (Copenh) 27 1-84
[5]  
Schellens JH(2004)Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males Br J Clin Pharmacol 58 142-155
[6]  
Grochow LB(2008)A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies Cancer Chemother Pharmacol 63 65-74
[7]  
Sparreboom A(1950)Simplification of drug dosage calculation by application of the surface area principle Pediatrics 5 783-790
[8]  
Basche M(1989)A formula to estimate the approximate surface area if height and weight be known. 1916 Nutrition 5 303-311
[9]  
Gustafson DL(2003)Model appropriateness and population pharmacokinetic modeling J Clin Pharmacol 43 610-623
[10]  
Holden SN(2002)Dosing strategies for anticancer drugs: the good, the bad and body-surface area Eur J Cancer 38 1677-1684